Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1-10. (Cancelled)

- 11. (New) A method of administering to a patient a sublingual pharmaceutical formulation for the treatment of inflammatory symptoms of various type, generally associated with pain and fever, said pharmaceutical formulation comprising at least one non-steroidal anti-inflammatory agent FANS, wherein the therapeutic dose of said anti-inflammatory agent in said sublingual formulation is drastically reduced in comparison with the therapeutic dose of the same anti-inflammatory agent in a pharmaceutical formulation for oral administration, which provides the same therapeutic effect.
- 12. (New) The method according to claim 11, in which the FANS agent is capable of being absorbed by the oral mucosa.
- 13. (New) The method according to claim 11, in which the FANS agent is selected among: nimesulide, ketoprofen, ibuprofen, paracetamol, diclofenac, naproxen, ketorolac, tenoxicam or pyroxicam.
- 14. (New) The method according to claim 11, in which said sublingual pharmaceutical formulation further contains a water soluble excipient and/or a crystalline water insoluble excipient with a disintegrating function.

- 15. (New) The method according to claim 14, in which said water soluble excipient is mannitol.
- 16. (New) The method according to claim 14, in which said crystalline water insoluble excipient with a disintegrating function is microcrystalline cellulose.
- 17. (New) The method according to claim 11, in which said sublingual pharmaceutical formulation further contains a lubricant.
- 18. (New) The method according to claim 17, in which said lubricant is magnesium stearate and/or PEG 6000 powder.
- 19. (New) The method according to claim 11, in which said sublingual pharmaceutical formulation further contains a sweetener.
- 20. (New) The method according to claim 19, in which said sweetener is sodium saccharate.
- 21. (New) The method according to claim 11, in which said sublingual pharmaceutical formulation is in a pharmaceutical form selected among: gel, granulate, powder, freeze-dried product, pressed capsule or pill.